Axel Bolte

2021

In 2021, Axel Bolte earned a total compensation of $2.6M as President and Chief Executive Officer at Inozyme Pharma, a 51% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$250,960
Option Awards$1,734,309
Salary$544,205
Other$94,499
Total$2,623,972

Bolte received $1.7M in option awards, accounting for 66% of the total pay in 2021.

Bolte also received $251K in non-equity incentive plan, $544.2K in salary and $94.5K in other compensation.

Rankings

In 2021, Axel Bolte's compensation ranked 4,969th out of 12,415 executives tracked by ExecPay. In other words, Bolte earned more than 60.0% of executives.

ClassificationRankingPercentile
All
4,969
out of 12,415
60th
Division
Manufacturing
2,087
out of 5,501
62nd
Major group
Chemicals And Allied Products
891
out of 2,371
62nd
Industry group
Drugs
798
out of 2,092
62nd
Industry
Pharmaceutical Preparations
567
out of 1,542
63rd
Source: SEC filing on April 27, 2022.

Bolte's colleagues

We found three more compensation records of executives who worked with Axel Bolte at Inozyme Pharma in 2021.

2021

Deborah Wenkert

Inozyme Pharma

Chief Medical Officer

2021

Henric Bjarke

Inozyme Pharma

Chief Operating Officer

2021

Steven Jungles

Inozyme Pharma

Former Senior Vice President and Chief Technical Operations Officer

News

In-depth

You may also like